Cassava Sciences Inc
Cassava Sciences Inc (SAVA) is a small‑cap biotechnology company focused on developing therapies for neurodegenerative disorders, most notably Alzheimer’s disease. Its value proposition centres on a research‑driven pipeline and clinical programmes that aim to address disease mechanisms rather than symptoms. As a market cap of around $192 million suggests, the company is in the speculative phase: progress depends heavily on clinical trial results, regulatory review and scientific validation. Investors should expect significant volatility and binary outcomes tied to trial readouts or regulatory actions. Financial runway, partnership deals and the quality and reproducibility of clinical data are critical factors to monitor. This summary is for general educational purposes only and not investment advice; investors should carry out their own research, consider their risk tolerance, and consult a qualified adviser before making decisions. Past performance is not a guide to future results and capital is at risk.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Cassava Sciences' stock with a target price of $75, indicating potential growth.
Financial Health
Cassava Sciences is showing solid cash flow and book value, indicating a stable financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring SAVA
Early Alzheimer's Detection: Could Blood Tests Replace Scans?
The FDA's approval of Roche and Eli Lilly's blood test marks a pivotal shift toward early and accessible Alzheimer's diagnosis in primary care. This breakthrough is expected to accelerate growth for companies in the diagnostics sector and expand the market for new Alzheimer's treatments.
Published: October 14, 2025
Explore BasketBeyond Leqembi: The Alzheimer's Treatment Frontier
New long-term data shows Eisai and Biogen's Alzheimer's drug, Leqembi, effectively slows cognitive decline over four years, confirming its market-leading position. This breakthrough validates the underlying scientific approach, creating investment opportunities in other companies developing similar neurodegenerative therapies and diagnostic tools.
Published: July 30, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical readouts matter
Upcoming trial results and regulatory updates can rapidly change valuation, though outcomes can be binary and unpredictable.
Research‑driven upside
If clinical data are positive, the company could see substantial appreciation; investors should weigh potential reward against high risk.
Scientific scrutiny relevant
Peer‑review, regulatory commentary and independent analysis are important to assess credibility, while remembering biotech outcomes can vary.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
